• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

Comprehensive Overview of 5-Amino-2-methylpyridine-3-acetonitrile (CAS No. 1807098-30-1): Properties, Applications, and Industry Insights

5-Amino-2-methylpyridine-3-acetonitrile (CAS 1807098-30-1) is a specialized organic compound gaining traction in pharmaceutical and agrochemical research due to its unique molecular structure. As a derivative of pyridine, this nitrile-functionalized compound exhibits versatile reactivity, making it a valuable intermediate in synthetic chemistry. The presence of both amino and methyl groups on the pyridine ring enhances its potential for selective modifications, a feature highly sought after in drug discovery pipelines.

Recent studies highlight the compound's role in developing kinase inhibitors, a hot topic in oncology research. With the global kinase inhibitor market projected to exceed $130 billion by 2030, intermediates like 5-Amino-2-methylpyridine-3-acetonitrile are witnessing increased demand. Its acetonitrile moiety particularly facilitates cross-coupling reactions, answering frequent search queries about "nitrile-containing building blocks for medicinal chemistry." Analytical data confirms >98% purity in commercial batches, with characteristic IR peaks at 2220 cm^-1 (C≡N stretch) and 3350 cm^-1 (N-H stretch).

Environmental considerations are addressed through the compound's biodegradability profile, aligning with trending searches for "green chemistry intermediates." The 2-methylpyridine core demonstrates lower aquatic toxicity compared to halogenated analogs, per OECD 301F testing protocols. This positions CAS 1807098-30-1 as a sustainable choice for researchers investigating "eco-friendly heterocyclic compounds" – a keyword phrase with 320% growth in academic database searches since 2022.

Process chemists frequently inquire about "large-scale synthesis of amino-substituted pyridines." Optimized routes for 5-Amino-2-methylpyridine-3-acetonitrile employ catalytic amination (Pd/Xantphos system) with 85-90% yields, as documented in recent patent literature (WO2022155513). The compound's melting point (148-151°C) and solubility profile (soluble in DMSO, ethanol) make it particularly useful for automated synthesis platforms – a key consideration for pharmaceutical companies investing in AI-driven drug discovery.

Emerging applications include its use in OLED materials, responding to the booming demand for flexible displays. The electron-withdrawing cyano group in 3-acetonitrile derivatives enhances charge transport properties, with recent Journal of Materials Chemistry reports demonstrating 18% improved luminescence efficiency in test devices. This connects with high-volume searches for "organic semiconductors with pyridine cores."

Quality control protocols for CAS 1807098-30-1 typically involve HPLC (C18 column, 0.1% TFA/ACN gradient) with UV detection at 254 nm. These analytical parameters address common purchaser concerns about "HPLC methods for pyridine derivative purity verification." The compound's stability under nitrogen atmosphere (-20°C storage) ensures reliable performance in multi-step syntheses, a critical factor for contract manufacturing organizations.

With the custom synthesis market growing at 7.2% CAGR, suppliers of 5-Amino-2-methylpyridine-3-acetonitrile are expanding cGMP-compliant production capabilities. This responds to pharmaceutical industry demands documented in recent FDA filings that reference this intermediate in investigational new drug applications. The compound's molecular weight (161.18 g/mol) and LogP (1.2) fall within optimal ranges for blood-brain barrier penetration, explaining its prevalence in CNS drug discovery projects.

Academic interest is reflected in the 47% increase in SciFinder citations since 2020, particularly for methodologies involving regioselective functionalization of the pyridine ring. The compound's X-ray crystallography data (CCDC 2058875) reveals planar geometry with intermolecular hydrogen bonding – structural features frequently queried in computational chemistry forums discussing "non-covalent interactions in drug design."

Industrial scale-up challenges are being addressed through continuous flow chemistry approaches, with recent ACS Sustainable Chemistry publications reporting 92% space-time yields for 5-Amino-2-methylpyridine-3-acetonitrile production. This innovation directly tackles manufacturer searches for "process intensification of nitrile syntheses." The compound's compatibility with photoredox catalysis (demonstrated in Nature Catalysis 2023) further expands its utility in modern synthetic strategies.

Global regulatory status remains favorable, with CAS 1807098-30-1 listed in REACH Annex VII inventories. This compliance information addresses 78% of procurement officer queries regarding "EU-compliant specialty chemicals." The compound's LD50 (>2000 mg/kg oral, rat) and absence of mutagenicity (Ames test negative) make it preferable for preclinical development compared to structurally similar alternatives.

Future research directions likely focus on the compound's potential in proteolysis targeting chimeras (PROTACs), a trending area capturing 23% of recent medicinal chemistry investment. The amino group's capacity for linker attachment positions this intermediate as a candidate for targeted protein degradation studies – a connection evidenced by 142% growth in related patent applications since 2021.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)